RxDoctor Payments Data

Jonathan Amos, MD

Rheumatology · Overland Park, KSNPI 1740660604

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.

$3,942in general payments, 2019–2025

Across 192 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$782
  • Amgen$647
  • UCB, Inc.$410
  • Johnson & Johnson$356
  • Pfizer$294
  • AstraZeneca$286
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,942100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,942 in reported general payments places this provider in the 70th percentile of 49 rheumatology providers in Kansas.

See all rheumatology providers in Kansas

Medicare billing

Part B allowed, 2024
$1,468,390
Medicare patients
385
Services billed
112,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxychloroquine Sulfate139$9,030
MethotrexateMethotrexate Sodium76$2,078
Mycophenolate Mofetil11$1,693
Prednisone116$1,032
Sulfasalazine18$737
Colchicine18$416
Methylprednisolone24$250
Methotrexate SodiumMethotrexate Sodium/Pf17$202
Folic Acid22$197
Allopurinol19$178
Duloxetine Hcl12$155
Tramadol Hcl26$69
Omeprazole13$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Colchicine$22$41618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 49 rheumatology providers in Kansas.

Other rheumatology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →